Aktuellt
SENASTE
In Q2 Calliditas regains the sequential sales growth but the conversion from patient enrollment into prescriptions and sales remains a challenge even if it is improving. Our take is that it is this conversion that is the main reason for a reduced 2023 product sales guide. Calliditas reduces the mid-point guide by 18-19%. Our updated view is a base case valuation of SEK 295 (310) and a Bull Case of SEK 445 (485) and a Bear Case of SEK 75 (85)
LÄS MER
